This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

ResApp Health Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Healthcare Services Gewinnwachstum	24.4%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	None
Zuletzt aktualisiert	n/a

Jüngste Aktualisierungen zum künftigen Wachstum

Analysts Are Optimistic We'll See A Profit From ResApp Health Limited (ASX:RAP)

Feb 25

Recent updates

In diesem Abschnitt stellen wir normalerweise Umsatz- und Gewinnwachstumsprognosen vor, die auf den Konsensschätzungen professioneller Analysten basieren, um den Anlegern zu helfen, die Fähigkeit des Unternehmens zur Gewinnerzielung zu verstehen. Da ResApp Health jedoch nicht genügend Daten aus der Vergangenheit zur Verfügung gestellt hat und keine Analystenprognose vorliegt, können die zukünftigen Erträge nicht zuverlässig durch Extrapolation von Vergangenheitsdaten oder anhand von Analystenprognosen berechnet werden.

Dies ist eine recht seltene Situation, da 97 % der von SimplyWall St erfassten Unternehmen über Finanzdaten aus der Vergangenheit verfügen.

Gewinn- und Umsatzwachstumsprognosen

ASX:RAP - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (AUD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
6/30/2022	4	-7	-4	-4	N/A
3/31/2022	3	-7	-5	-5	N/A
12/31/2021	0	-7	-6	-6	N/A
9/30/2021	0	-7	-6	-6	N/A
6/30/2021	1	-7	-6	-6	N/A
3/31/2021	1	-7	-6	-6	N/A
12/31/2020	0	-8	-6	-6	N/A
9/30/2020	0	-8	-5	-5	N/A
6/30/2020	N/A	-8	-4	-4	N/A
3/31/2020	N/A	-7	N/A	N/A	N/A
12/31/2019	N/A	-6	-3	-3	N/A
9/30/2019	N/A	-6	-4	-4	N/A
6/30/2019	N/A	-5	-5	-5	N/A
3/31/2019	0	-6	N/A	N/A	N/A
12/31/2018	0	-7	-6	-6	N/A
9/30/2018	0	-7	-6	-6	N/A
6/30/2018	N/A	-7	-5	-5	N/A
3/31/2018	0	-6	N/A	N/A	N/A
12/31/2017	0	-6	-6	-6	N/A
9/30/2017	0	-8	-6	-6	N/A
6/30/2017	N/A	-10	-5	-5	N/A
3/31/2017	N/A	-10	-4	-4	N/A
12/31/2016	N/A	-9	-3	-3	N/A
9/30/2016	N/A	-6	-3	-3	N/A
6/30/2016	N/A	-3	-2	-2	N/A
3/31/2016	0	-3	N/A	-2	N/A
12/31/2015	0	-2	N/A	-1	N/A
9/30/2015	0	-1	N/A	-1	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Insufficient data to determine if RAP's forecast earnings growth is above the savings rate (1.8%).

Ertrag vs. Markt: Insufficient data to determine if RAP's earnings are forecast to grow faster than the Australian market

Hohe Wachstumserträge: Insufficient data to determine if RAP's earnings are expected to grow significantly over the next 3 years.

Einnahmen vs. Markt: Insufficient data to determine if RAP's revenue is forecast to grow faster than the Australian market.

Hohe Wachstumseinnahmen: Insufficient data to determine if RAP's revenue is forecast to grow faster than 20% per year.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Insufficient data to determine if RAP's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

ResApp Health Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Forecast breakeven moved forward to 2021

Analysts Are Optimistic We'll See A Profit From ResApp Health Limited (ASX:RAP)

Recent updates

Pfizer Australia Holdings Pty Limited completed the acquisition of ResApp Health Limited (ASX:RAP).

Full year 2022 earnings released: AU$0.008 loss per share (vs AU$0.009 loss in FY 2021)

ResApp Health Limited to Report Q4, 2022 Results on Jul 27, 2022

ResApp Health Limited Receives FDA 510(K) Clearance for Sleepcheckrx

ResApp Health Limited Announces Results from Data Confirmation Study

No independent directors

No independent directors

ResApp Health Limited to Report Q3, 2022 Results on Apr 26, 2022

Pfizer Australia Holdings Pty Limited agreed to acquire ResApp Health Limited (ASX:RAP) for approximately AUD 100 million.

Pfizer Australia Holdings Pty Limited agreed to acquire ResApp Health Limited (ASX:RAP) for approximately AUD 100 million.

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

ResApp Health Limited Completes Recruitment in its U.S. Covid-19 Clinical Study

Is ResApp Health (ASX:RAP) In A Good Position To Invest In Growth?

ResApp Receives Regulatory Approvals for Cough Counter

ResApp Health Limited Completes COVID-19 Study Recruitment in India

ResApp Health Limited Receives Advanced and Overseas R&D Finding

ResApp Health Limited Receives Regulatory Approval in Indonesia

Is ResApp Health (ASX:RAP) In A Good Position To Invest In Growth?

Medgate Extends European ResAppDx Trial

Forecast breakeven moved forward to 2021

ResApp Health Limited Reports Recruited the First Participant in Its US-Based Clinical Study to Explore the Relationship Between Cough and SARS-Cov2 Infection

Here's Why We're Watching ResApp Health's (ASX:RAP) Cash Burn Situation

ResApp to Progress Clinical Study to Develop Covid-19 Smartphone-Based Screening Test

Medgate AG Commences ResApp Health Limited 's European ResAppDx Trial

Resapp Health Limited Achieves CE Mark for Wearable Device

ResApp Health Limited Provides an Update on its Two-Year, Non-Exclusive Software Licencing Agreement with Workplace Medicine Australia Ltd

ResApp Health Limited Announces Resignation of Stephen Hewitt-Dutton as Joint Company Secretary

Analysts Are Optimistic We'll See A Profit From ResApp Health Limited (ASX:RAP)

ResApp Health Limited Files Pre-Submission Package with the United States Food and Drug Administration

ResApp Health Limited Strengthens Patent Position in Europe

ResApp Health Limited to Report Q2, 2021 Results on Jan 29, 2021

Resapp Health Limited Appoints Mike Connell as Vice President, Commercial

ResApp Health Limited Launches SleepCheck

Companies Like ResApp Health (ASX:RAP) Are In A Position To Invest In Growth

ResApp Health Limited Releases Version 2.3 of its ResAppDx Smartphone Application

ResApp Health Limited Appoints Stephen Hewitt-Dutton as Joint Company Secretary

ResApp Health Limited Signs Non-Exclusive, Two-Year Software Licensing Agreement with Workplace Medicine Australia Ltd

Medgate to Pilot ResAppDx for Telehealth Across Europe

ResApp Health Limited to Report Q1, 2021 Results on Oct 30, 2020

ResApp Health Limited Files Pre-Submission Package with the United States Food and Drug Administration

ResApp Health Limited to Report Q4, 2020 Results on Jul 29, 2020

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken